Human VEGFR2/KDR/Flk-1 Antibody

Catalog # Availability Size / Price Qty
AF357
AF357-SP
Human VEGFR2/KDR/Flk-1 Antibody in Data
4 Images
Product Details
Citations (28)
FAQs
Supplemental Products
Reviews

Human VEGFR2/KDR/Flk-1 Antibody Summary

Species Reactivity
Human
Specificity
Detects human VEGFR2/KDR/Flk‑1 in direct ELISAs and Western blots. In direct ELISAs, approximately 40% cross-reactivity with recombinant mouse VEGFR2 is observed and less than 10% cross-reactivity with recombinant human (rh) VEGFR1 and rhVEGFR3 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human VEGFR2/KDR/Flk-1
Ala20-Glu764
Accession # AAC16450
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 0.05-0.25 µg/mL in the presence of 30 ng/mL Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Human VEGF165.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Western Blot Detection of Human VEGFR2/KDR/Flk‑1 by Western Blot. View Larger

Detection of Human VEGFR2/KDR/Flk‑1 by Western Blot. Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for VEGFR2/KDR/Flk-1 at approximately 200-250 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry VEGFR2/KDR/Flk‑1 in Human Placenta. View Larger

VEGFR2/KDR/Flk‑1 in Human Placenta. VEGFR2/KDR/Flk-1 was detected in immersion fixed paraffin-embedded sections of human placenta using 15 µg/mL Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-AEC Cell & Tissue Staining Kit (red; Catalog # CTS009) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Immunohistochemistry VEGFR2/KDR/Flk‑1 in Human Kidney. View Larger

VEGFR2/KDR/Flk‑1 in Human Kidney. VEGFR2/KDR/Flk-1 was detected in immersion fixed paraffin-embedded sections of human kidney using Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Neutralization VEGFR2/KDR/Flk‑1 Inhibi-tion of VEGF-dependent Cell Proliferation and Neutral-ization by Human VEGFR2/KDR/Flk‑1 Anti-body. View Larger

VEGFR2/KDR/Flk‑1 Inhibi-tion of VEGF-dependent Cell Proliferation and Neutral-ization by Human VEGFR2/KDR/Flk‑1 Anti-body. Recombi-nant Human VEGFR2/KDR/Flk-1 Fc Chi-mera (Catalog # 357-KD) inhibits Recombinant Human VEGF165(Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF165(5 ng/mL) activity elicited by Recombinant Human VEGFR2/KDR/Flk-1 Fc Chi-mera (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF357). The ND50is typically 0.05-0.25 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs
3791 (Human); 16542 (Mouse)
Alternate Names
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Datasheets

Citations for Human VEGFR2/KDR/Flk-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

28 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Atypical chemokine receptor ACKR3/CXCR7 controls postnatal vasculogenesis and arterial specification by mesenchymal stem cells via Notch signaling
    Authors: ST Wei, YC Huang, ML Hsieh, YJ Lin, WC Shyu, HC Chen, CH Hsieh
    Cell Death Dis, 2020;11(5):307.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Western Blot
  2. ATF-2 and Tpl2 regulation of endothelial cell cycle progression and apoptosis
    Authors: GW Fearnley, AM Latham, M Hollstein, AF Odell, S Ponnambala
    Cell. Signal., 2019;66(0):109481.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  3. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant
    Authors: V Veschi, LR Mangiapane, A Nicotra, S Di Franco, E Scavo, T Apuzzo, DS Sardina, M Fiori, A Benfante, ML Colorito, G Cocorullo, F Giuliante, C Cipolla, G Pistone, MR Bongiorno, A Rizzo, CM Tate, X Wu, S Rowlinson, LF Stancato, M Todaro, R De Maria, G Stassi
    Oncogene, 2019;0(0):.
    Species: Xenograft
    Sample Types: Whole Tissue
    Applications: IHC-P
  4. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis
    Authors: G Genet, K Boyé, T Mathivet, R Ola, F Zhang, A Dubrac, J Li, N Genet, L Henrique G, L Benedetti, S Künzel, L Pibouin-Fr, JL Thomas, A Eichmann
    Nat Commun, 2019;10(1):2350.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling
    Authors: Y Jin, L Muhl, M Burmakin, Y Wang, AC Duchez, C Betsholtz, HM Arthur, L Jakobsson
    Nat. Cell Biol., 2017;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  6. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4
    Authors: LD Volk-Drape, KL Hall, AC Wilber, S Ran
    PLoS ONE, 2017;12(6):e0179257.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  7. Affimer proteins are versatile and renewable affinity reagents
    Authors: C Tiede, R Bedford, SJ Heseltine, G Smith, I Wijetunga, R Ross, D AlQallaf, AP Roberts, A Balls, A Curd, RE Hughes, H Martin, SR Needham, LC Zanetti-Do, Y Sadigh, TP Peacock, AA Tang, N Gibson, H Kyle, GW Platt, N Ingram, T Taylor, LP Coletta, I Manfield, M Knowles, S Bell, F Esteves, A Maqbool, RK Prasad, M Drinkhill, RS Bon, V Patel, SA Goodchild, M Martin-Fer, RJ Owens, JE Nettleship, ME Webb, M Harrison, JD Lippiat, S Ponnambala, M Peckham, A Smith, PK Ferrigno, M Johnson, MJ McPherson, DC Tomlinson
    Elife, 2017;6(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  8. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling
    Authors: K Heinolaine, S Karaman, G D'Amico, T Tammela, R Sormunen, L Eklund, K Alitalo, G Zarkada
    Circ. Res, 2017;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  9. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation via macropinocytosis
    J Cell Sci, 2016;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Authors: Fiorio Pla, Alessand, Brossa, Alessia, Bernardini, Michela, Genova, Tullio, Grolez, Guillaum, Villers, Arnaud, Leroy, Xavier, Prevarskaya, Natalia, Gkika, Dimitra, Bussolati, Benedett
    BMC Cancer, 2014;14(0):939.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  11. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions.
    Authors: Fearnley G, Odell A, Latham A, Mughal N, Bruns A, Burgoyne N, Homer-Vanniasinkam S, Zachary I, Hollstein M, Wheatcroft S, Ponnambalam S
    Mol Biol Cell, 2014;25(16):2509-21.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  12. Sustained delivery of VEGF maintains innervation and promotes reperfusion in ischemic skeletal muscles via NGF/GDNF signaling.
    Authors: Shvartsman, Dmitry, Storrie-White, Hannah, Lee, Kangwon, Kearney, Cathal, Brudno, Yevgeny, Ho, Nhi, Cezar, Christin, McCann, Corey, Anderson, Erin, Koullias, John, Tapia, Juan Car, Vandenburgh, Herman, Lichtman, Jeff W, Mooney, David J
    Mol Ther, 2014;22(7):1243-53.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  13. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors.
    Authors: Etulain J, Negrotto S, Tribulatti M, Croci D, Carabelli J, Campetella O, Rabinovich G, Schattner M
    PLoS ONE, 2014;9(4):e96402.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  14. Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype.
    Authors: Orecchia A, Mettouchi A, Uva P, Simon G, Arcelli D, Avitabile S, Ragone G, Meneguzzi G, Pfenninger K, Zambruno G, Failla C
    FASEB J, 2014;28(2):692-704.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  15. MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA).
    Authors: Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson A, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, Gerwins P, Kjellen L, Kreuger J
    J Biol Chem, 2013;288(36):25956-63.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  16. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development.
    Authors: Goldman O, Han S, Sourisseau M, Dziedzic N, Hamou W, Corneo B, D'Souza S, Sato T, Kotton D, Bissig K, Kalir T, Jacobs A, Evans T, Evans M, Gouon-Evans V
    Cell Stem Cell, 2013;12(6):748-60.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  17. Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.
    Authors: Gourlaouen, Morgane, Welti, Jonathan, Vasudev, Naveen S, Reynolds, Andrew R
    J Biol Chem, 2013;288(11):7467-80.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  18. Differential expression of Vegfr-2 and its soluble form in preeclampsia.
    Authors: Munaut C, Lorquet S, Pequeux C, Coulon C, Le Goarant J, Chantraine F, Noel A, Goffin F, Tsatsaris V, Subtil D, Foidart JM
    PLoS ONE, 2012;7(3):e33475.
    Species: Human
    Sample Types: Plasma
    Applications: Western Blot
  19. Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis.
    Authors: Lee HS, Myers A, Kim J
    Am. J. Respir. Crit. Care Med., 2009;180(11):1056-67.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  20. The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice.
    Authors: Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, Hamakubo T, Ryeom S, Aird WC, Kodama T
    J. Clin. Invest., 2009;119(8):2257-70.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  21. Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo.
    Authors: Asikainen TM, Waleh NS, Schneider BK, Clyman RI, White CW
    Am. J. Physiol. Lung Cell Mol. Physiol., 2006;291(4):L588-95.
    Species: Primate - Papio anubis (Olive Baboon)
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  22. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential.
    Authors: Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T
    Am. J. Pathol., 2006;169(4):1167-82.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  23. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung.
    Authors: Asikainen TM, Schneider BK, Waleh NS, Clyman RI, Ho WB, Flippin LA, Gunzler V, White CW
    Proc. Natl. Acad. Sci. U.S.A., 2005;102(29):10212-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  24. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
    Authors: Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
    Invest. Ophthalmol. Vis. Sci., 2004;45(2):368-74.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  25. PEDF derived from glial Muller cells: a possible regulator of retinal angiogenesis.
    Authors: Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A
    Exp. Cell Res., 2004;299(1):68-78.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  26. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
    Authors: Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Almici C, Caramatti C, Mangoni L, Rizzoli V
    Blood, 2003;102(2):638-45.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  27. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
    Int. J. Cancer, 2003;104(5):603-10.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  28. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.
    Authors: Okruzhnov Y, Nicholas J
    J. Virol., 2001;75(22):10933-40.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Cell and Tissue Staining Kits

Immunohistochemistry Reagents

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human VEGFR2/KDR/Flk-1 Antibody

There are currently no reviews for this product. Be the first to review Human VEGFR2/KDR/Flk-1 Antibody and earn rewards!

Have you used Human VEGFR2/KDR/Flk-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review